# KLOW Peptide Results in the Research Literature — Component Tissue-Repair Findings > KLOW results from the component research literature — the tissue-repair findings for BPC-157, thymosin beta-4 (TB-500), KPV and GHK-Cu that inform the blend rationale. Cited, component-attributed, honest about the blend gap. What the tissue-repair component studies have actually measured. BPC-157 tendon and ligament results, thymosin β4 wound results, KPV anti-inflammatory results, GHK-Cu matrix results — each attributed to its source, each distinguished from blend-level claims. ## In plain English KLOW results, honestly stated: the results are from individual peptide studies, not from a KLOW blend study. That is not a marketing caveat — it is the structural fact of this research field. No controlled trial has tested the four-peptide blend. So the results on this page are the best available evidence for what each arm of KLOW can do on its own. The lens for this site is tissue repair and tendon healing — the area where the BPC-157 and TB-500/thymosin β4 component literatures are deepest. The KPV and GHK-Cu findings are documented here as their own evidence columns, not as supporting acts. Together, these four evidence lines are what KLOW research is built on. ## BPC-157 tendon and tissue-repair results The KLOW results that most directly address tendon and connective-tissue repair come from the BPC-157 arm. In the foundational 2003 study by Staresinic et al. in the Journal of Orthopaedic Research, BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic and macroscopic measures at doses of 10 μg, 10 ng or 10 pg per rat (intraperitoneal, once daily) and stimulated tendocyte outgrowth in vitro [2]. Load-to-failure, tissue organization and functional recovery were all improved versus untreated controls. In the 2006 Krivic et al. study, BPC-157 promoted tendon-to-bone healing after Achilles detachment in rats and counteracted corticosteroid-induced aggravation of the injury — a finding relevant to the common context of steroid-treated tendinopathy [9]. In the 2010 Cerovecki et al. study, BPC-157 (under the clinical designation PL 14736) improved healing of a transected rat medial collateral ligament across biomechanical, functional and microscopic measures [10]. At the cellular level, the 2011 Chang et al. in vitro study demonstrated that BPC-157 enhances tendon fibroblast outgrowth, survival and migration, with effects linked to the FAK-paxillin signaling pathway [11]. This is the cellular mechanism underlying the tissue-level repair observations. A 2025 narrative review (Curr Rev Musculoskelet Med) summarized the state of the BPC-157 musculoskeletal evidence: promising animal-model results, only three published human pilots, and a recommendation to treat the compound as investigational [13]. Recent extensions of the research: a 2026 paper documented fistula resolution linked to BPC-157's nitric-oxide system modulation [14], and a 2025 study found reduced liver, kidney and lung injury in rats with acute pancreatitis [15] — extending the tissue-protection evidence beyond the musculoskeletal focus. ## TB-500 / thymosin β4 wound results The TB-500 arm's tissue-repair results derive primarily from the native thymosin β4 protein. The 1999 Malinda et al. study in the Journal of Investigative Dermatology is the anchor finding [1]: In a rat full-thickness wound model, topical or intraperitoneal thymosin β4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline controls. Wound contraction increased by at least 11% by day 7. Collagen deposition and angiogenesis were also raised. In migration assays, as little as 10 pg stimulated keratinocyte migration 2–3-fold. The attribution note: TB-500 (Ac-LKKTETQ) is the synthetic fragment of thymosin β4. Most wound-healing efficacy data — including the Malinda 1999 results — are for the full-length native protein, not the fragment. The LKKTET motif that TB-500 represents sequesters G-actin and is linked to cell migration, but the integrin-linked kinase activation and epicardial progenitor mobilization documented for native thymosin β4 have not been demonstrated for the fragment. When citing this finding to the KLOW TB-500 arm, that distinction is maintained. ## KPV anti-inflammatory results KPV results from the 2008 Dalmasso et al. study in Gastroenterology [3]: In human intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells, nanomolar KPV (10 nM) inhibited NF-kB p65/RelA nuclear import and MAP-kinase ERK/p38 activation, and reduced secretion of TNF-α, IL-6, IL-1β and IL-8. KPV was transported into cells via PepT1 (SLC15A1) with a Km of approximately 160 μM — and PepT1 is upregulated in inflamed intestinal tissue, giving KPV a tissue-selective uptake advantage in the inflamed gut. In vivo, oral KPV at 100 μM in drinking water reduced the severity of DSS-induced and TNBS-induced colitis in C57BL/6 mice [3]. The KLOW implication: the KPV component is the anti-inflammatory arm, acting through a mechanism complementary to the tissue-repair signaling of BPC-157 and TB-500. The evidence base is strongest in the gut-mucosa context; KPV's contribution to the KLOW blend's behavior in other tissues is a mechanistic extrapolation, not a tested result. ## GHK-Cu matrix synthesis results GHK-Cu results from the component literature: From the 2015 skin-regeneration review (Pickart, Vasquez-Soltero, Margolina, BioMed Research International): GHK-Cu stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin. Plasma GHK declines from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60. In a placebo-controlled clinical comparison, topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid, with documented improvements in skin laxity, clarity, fine lines, wrinkle depth and density [4]. From the 2018 gene-data review (Pickart, Margolina, IJMS): GHK modulates expression of approximately 31.2% of human genes at a 50%-or-greater change threshold, increasing 59% and suppressing 41% of affected genes, with the strongest signals on extracellular-matrix remodeling, the ubiquitin-proteasome system (41 genes up, 1 down) and DNA-repair and antioxidant gene sets at 1–10 nM concentrations [5]. GHK-Cu's evidence base is the most clinical of the four components — topical human data with placebo controls — though those data are in cosmetic and topical-wound applications rather than in the injectable context of the KLOW vial. ## The absent blend result Having documented the four evidence columns, the editorial integrity point follows: no [klow results](/results) study tests the combination. Every result on this page is a component result. The KLOW blend's clinical outcome — whether the four arms interact synergistically, additively, or at cross-purposes — has not been measured. A 2026 Sports Medicine review (Mendias & Awan, Sports Med) covering musculoskeletal peptide therapies including TB-500/thymosin beta-4 and BPC-157 concluded that many unapproved peptides show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [7]. That is the honest state of the evidence. The component literature is the strongest available basis; the blend gap is real. --- A single-hue reading room for the peer-reviewed component literature — four peptides, four separate evidence columns, and the untested blend column left in plain sight.